30 closest matches · ranked by relevance
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
Type1diabetes
Primary: Percentage of Time Spent With Dexcom CGMG < 60 mg/dl — 1.32; 1.95; 1.05; 0.99 percentage of time
Healthy
Primary: Mean Score of Sensory Attributes Based on Palatability Assessment Questionnaire at 1 Minute Post-dose on Day 1 — 80.3; 49.4; 54.0; 48.5 Units on a scale
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06821497 — 3302; 3375; 3479; 11220 ng*hr/mL
Upper Respiratory Tract Infections
Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants
Photoreceptor Sensitivity Thresholds
Primary: Time to Rod-cone Break (RCB) — 11.34; 9.98 Minutes
Cardiovascular Disease Other · Physical Activity
Primary: Moderate to Vigorous Physical Activity (MVPA) — -0.7; 8.8 Average change in minutes per day — p=.023
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Healthy Volunteers
Primary: Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition — 671.6; 145.1; 84.96 Nanogram per milliliter (ng/mL)
Hiv · Fatigue · Mobility Limitation
Primary: Change in Physical Function (Part 1) — -15.0; -12.6 Seconds — p=0.35
Healthy Participants
Primary: Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling — 666.4; 745.5 Nanogram*hour per milliliter…
Covid19 · SARS-CoV Infection · Corona Virus Infection
Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events
Obesity; Rurality
Primary: Participant Recruitment Rate — 99; 5 Participants
Healthy
Primary: Area Under the Concentration-Time Curve From Time Zero to The Time of The Last Quantifiable Concentration (AUClast) of Sisunatovir PIC Versus (vs) WGT in a Fasted State…
Healthy
Primary: Maximum Observed Concentration (Cmax) of Cis-Ceftibuten (CTB): Part 1 — 18170; 25470; 30510; 27120 Nanogram per milliliter (ng/mL)
Skin Diseases
Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids
Influenza
Primary: Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs) — 0; 0 Participants
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Etrasimod — 1620; 1529; 1538; 1391…
Intraosseous Vascular Access
Primary: Occurrences of Extravasation During Infusion — 2 participants
Aging
Primary: Number of Participants That Sustained >10% Caloric Restriction — 7; 12 Participants
Hypovitaminosis D
Primary: Plasma PTH Level — 58.29; 60.73; 57.88; 54.05 pg/ml
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib — 361.1; 370.1; 385.1 nanograms*hours/milliliter…
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 1.0; 1.0; 0.0; 0.5 Percentage of participants
Hypoglycemia · Diabetes Mellitus · Drug-Specific Antibodies
Primary: Percentage of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration — 95.7 percentage of participants
Cardiovascular Disease Other · Physical Activity
Primary: Moderate to Vigorous Physical Activity (MVPA) — -1.9; 3.4 average minutes per day — p=0.24